Regents of The University of California Invests $1.18 Million in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

Key Points

• The Regents of The University of California acquired approximately 81,884 shares of Centessa Pharmaceuticals PLC, valued at about $1.177 million, making it the fund's 6th largest holding.
• Insider activities show that CEO Saurabh Saha sold 55,000 shares while Director Arjun Goyal bought 417,646 shares, indicating varying confidence levels among company executives.
• Equities analysts have mixed ratings on Centessa Pharmaceuticals, with an average rating of "Moderate Buy" and a consensus price target around $28.10.

Regents of The University of California acquired a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 81,884 shares of the company's stock, valued at approximately $1,177,000. Centessa Pharmaceuticals makes up approximately 0.3% of Regents of The University of California's holdings, making the stock its 6th biggest position. Regents of The University of California owned 0.06% of Centessa Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd grew its holdings in Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after acquiring an additional 3,194 shares during the last quarter. Barclays PLC grew its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Centessa Pharmaceuticals during the first quarter valued at about $147,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $162,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $17.23, for a total value of $103,380.00. Following the completion of the sale, the general counsel owned 105,386 shares of the company's stock, valued at approximately $1,815,800.78. This represents a 5.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the sale, the insider directly owned 122,279 shares of the company's stock, valued at $1,902,661.24. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 236,322 shares of company stock worth $3,300,064 over the last quarter. 7.09% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA traded up $0.41 on Friday, reaching $18.05. The company's stock had a trading volume of 1,282,676 shares, compared to its average volume of 1,135,819. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $19.09. The company has a market cap of $2.42 billion, a P/E ratio of -10.08 and a beta of 1.48. The company has a 50-day simple moving average of $14.76 and a 200 day simple moving average of $14.49. The company has a debt-to-equity ratio of 0.32, a quick ratio of 14.37 and a current ratio of 10.11.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CNTA shares. Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective on the stock. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective on the stock. Chardan Capital restated a "buy" rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Truist Financial began coverage on shares of Centessa Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $30.00 price objective for the company. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $28.10.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.